Relationship between Diabetes Duration and Real-World Effectiveness of Second-Line Dual OAD Therapy

被引：0
|
作者：
Brath, Helmut
Paldanius, Paeivi M.
Bader, Giovanni
Mathieu, Chantal
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1220-P
引用
收藏
页码：A315 / A316
页数：2
相关论文
共 50 条
  • [21] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [22] The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
    Kim, Won Jun
    Noh, Jung Hyun
    Han, Kyungdo
    Park, Cheol-Young
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 81 (03) : 1263 - 1272
  • [23] Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data
    Ha, K. H.
    Kim, B.
    Choi, H.
    Kim, D. J.
    Kim, H. C.
    DIABETIC MEDICINE, 2017, 34 (09) : 1235 - 1243
  • [24] Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
    Wells, J. Connor
    Dudani, Shaan
    Gan, Chun Loo
    Stukalin, Igor
    Azad, Arun A.
    Liow, Elizabeth
    Donskov, Frede
    Yuasa, Takeshi
    Pal, Sumanta K.
    De Velasco, Guillermo
    Hansen, Aaron R.
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Powles, Thomas
    McGregor, Bradley A.
    Duh, Mei S.
    Huynh, Lynn
    Heng, Daniel Y. C.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 354 - 361
  • [25] Real-world data analysis of the utilization of second-line maintenance therapy for patients with advanced ovarian cancer.
    Reid, Robert Lawrence
    Xie, Yiqiong
    Shi, Junxin
    Wallace, Katrine L.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC
    Rizzo, Mimma
    Carteni, Giacomo
    Pappagallo, Giovanni
    FUTURE ONCOLOGY, 2014, 10 (12) : 1893 - 1896
  • [27] Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
    Nie, Caiyun
    Xu, Weifeng
    Lv, Huifang
    Gao, Xiaohui
    Li, Guofeng
    Chen, Beibei
    Wang, Jianzheng
    Liu, Yingjun
    Zhao, Jing
    He, Yunduan
    Wang, Saiqi
    Chen, Xiaobing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison
    Santoni, Matteo
    Aurilio, Gaetano
    Massari, Francesco
    Grande, Enrique
    Matrana, Marc R.
    Rizzo, Mimma
    De Giorgi, Ugo
    Incorvaia, Lorena
    Martignetti, Angelo
    Molina-Cerrillo, Javier
    Zabalza, Ignacio Ortego
    Mollica, Veronica
    Rizzo, Alessandro
    Battelli, Nicola
    Porta, Camillo
    CLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 285 - 295
  • [29] Second-line Therapy for Type 2 Diabetes
    Krome, Susanne
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (19) : 1127 - 1128
  • [30] Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia
    Vainer, Noomi
    Aarup, Kathrine
    Andersen, Michael Asger
    Wind-Hansen, Lise
    Nielsen, Tine
    Frederiksen, Henrik
    Enggaard, Lisbeth
    Poulsen, Christian Bjorn
    Niemann, Carsten U.
    Rotbain, Emelie C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (05) : 874 - 886
12345